Denali Therapeutics (DNLI) Capital Expenditures (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Capital Expenditures data on file, last reported at $2.5 million in Q1 2026.

• Quarterly Capital Expenditures fell 51.44% year-over-year to $2.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.9 million (up 67.23% YoY) and the FY2025 annual result came in at $9.5 million, up 697.15% from the prior year.
• Capital Expenditures grew to $2.5 million in Q1 2026 per DNLI's latest filing, from $1.5 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $6.8 million in Q2 2022 and bottomed at -$11.5 million in Q4 2022.
• The 5-year median for Capital Expenditures is $2.5 million (2026), against an average of $1.6 million.
• The widest annual swing landed in 2023, when Capital Expenditures soared 5228.95%; it then sank 530.78% in 2024.
• Tracing DNLI's Capital Expenditures over 5 years: stood at -$11.5 million in 2022, then surged by 119.4% to $2.2 million in 2023, then slumped by 530.78% to -$9.6 million in 2024, then jumped by 115.83% to $1.5 million in 2025, then surged by 61.81% to $2.5 million in 2026.
• Per Business Quant, the three latest DNLI Capital Expenditures figures stand at $2.5 million (Q1 2026), $1.5 million (Q4 2025), and -$1.4 million (Q3 2025).

Peer Comparison